Extension usage examples:
Here's how our browser extension sees the article:
Article summary:
1. This study investigated whether whole-liver enhancing tumor burden (ETB) can serve as an imaging biomarker and help predict survival better than World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and European Association for the Study of the Liver (EASL) methods in patients with multifocal, bilobar neuroendocrine liver metastases (NELM).
2. Treatment response occurred in 5.9% (WHO criteria), 2.0% (RECIST), 25.5% (mRECIST), and 23.5% (EASL criteria) of patients, while ETB response was seen in 60.8%, 39.2%, and 21.6% of patients, respectively, with 30%, 50%, and 65% cutoffs.
3. ETB response was the only biomarker associated with a survival difference between responders and nonresponders, providing the best survival model with a 50% cutoff.
Article analysis:
This article is generally trustworthy and reliable due to its clear methodology, detailed results, and thorough discussion of implications for further research. The authors provide evidence to support their claims by citing relevant studies from other researchers in the field as well as their own data from this study's 51 participants. Furthermore, they discuss potential limitations such as small sample size or lack of long-term follow-up data which could affect the accuracy of their findings. Additionally, they note that further research is needed to confirm their results before any definitive conclusions can be made about using ETB as an imaging biomarker for predicting patient survival after TACE treatment for NELM metastases. All these points indicate that the authors have taken into consideration possible biases or missing points of consideration when conducting this study and presenting its results, making it a reliable source of information on this topic.